2021 International Congress on Myeloproliferative Neoplasms (2021 MPN Congress) is scheduled for October 28-29, 2021 at the New York Marriott at the Brooklyn Bridge in Brooklyn, New York. The 2021 MPN Congress is designed as a hybrid event this year, so all content will be available on the virtual platform for those unable to travel.

This year marks the 20th anniversary of the MPN Congress, an event that has become very popular over the past two decades- providing timely, relevant and meaningful information concerning the diagnosis and treatment of myeloproliferative neoplasms to attendees from around the world. The highly anticipated MPN Congress has always emphasized faculty interaction, audience participation and personal, collegial discussion among attendees, all of which have contributed significantly to the success of this meeting over the years.

The program for the 2021 MPN Congress will offer new information on the prognostic significance of leukocytosis in polycythemia vera, an approach to the differential diagnosis of hereditary erythrocytosis, an update on the clinical status of currently used MPN drugs, as well as new agents of potential value in the MPNs. The role of inflammation in conjunction with the biology and treatment of fatigue in MPN patients, and ruxolitinib-associated weight gain will be discussed.

Other presentations will include the new ELN recommendations for CML treatment, the hypereosinophilias, the status of diagnosis and therapy of mastocytosis, and an update on clinical predictors helpful in MPN transplantation decisions. The differential diagnosis of thrombocytosis and the significance of clonal hematopoiesis, the prognostic role of NGS in MPNs, as well as a review of Covid-19 and its impact on the management of MPNs will round out the program.

Accreditation

The Institute for Medical and Nursing Education, Inc. designates this live activity for a maximum of 11.25 AMA PRA Category 1 Credits.™

Target Audience

This educational activity is intended for hematologists, medical oncologists, translational scientists, and other healthcare professionals (physicians, clinicians, physicians-in-training, oncology nurses, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with myeloproliferative neoplasms and related disorders.

Educational Objectives

• Understand the molecular pathogenesis of myeloproliferative neoplasms (MPNs) and related disorders.
• Discuss the role and utilization of current approved therapies in MPNs, including the recent advances in therapeutics.
• Describe the potential role of agents in development for MPNs.
• Assess how to manage symptoms and therapy-associated adverse events for patients with MPNs.
• Outline the current treatment strategies (including first-line therapy, milestones, changing treatment, discontinuation and pregnancy) for patients with chronic myeloid leukemia (CML).

Abstract Submission

The committee seeks original papers that address basic or clinical issues specifically related to the diagnosis or management of patients with myeloproliferative neoplasms or chronic myeloid leukemia.

Participants interested in presenting data should submit abstracts by email to abstracts@mpncongress.com on or before September 19, 2021. 

For more information please visit the official event page.